GLOPERBA (colchicine) by Hikma is colchicine's effectiveness as a prophylactic treatment for gout has been postulated to be due to its ability to block neutrophil mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Approved for gout. First approved in 2019.
Drug data last refreshed 20h ago
Colchicine's effectiveness as a prophylactic treatment for gout has been postulated to be due to its ability to block neutrophil mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby…
Alkaloid
A Study to Evaluate Efficacy and Safety of Anakinra in Chinese Patients With Colchicine-resistent FMF
Colchicine for the Prevention of Recurrence in Cerebral Amyloid Angiopathy RElated IntraCerebral Hemorrhage
MACT (Mono Antiplatelet and Colchicine Therapy) Prospective Multicenter Study
Efficacy and Safety of Colchicine After PCI
CMP-MYTHiC Trial and Registry - CardioMyoPathy With MYocarditis THerapy With Colchicine
Worked on GLOPERBA at Hikma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo